Arbaclofen Placarbil

DB08892InvestigationalSmall molecule

Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by... It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

Chemical structure of Arbaclofen Placarbil
Mechanism
Curator reviewed
Primary indication
Investigated for the treatment of spasticity in multiple sclerosis, acute back spasms, and GERD.Curator reviewed
Formula / weight
C19H26ClNO6 · 399.87 g/mol (avg)
Code names
XP19986

Resolves to

Compound
UNIIW89H91R7VXCAS847353-30-4ChEMBLCHEMBL2107312PubChem11281011KEGGD08861
Structure
InChIKeyJXTAALBWJQJLGN-KSSFIOAISA-NSMILESCC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C
Targets
Q9UBS5GABBR1O75899GABBR2Q99928GABRG3
Transporters
P53985SLC16A1

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
671Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
22+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Arbaclofen Placarbil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In